ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$11.43
-0.14 (-1.21%)
âŧ
5d:
+0.7%
30d:
+75.04%
90d:
+103.38%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 27, 2026 at $12.40 · last confirmed Aug 31, 2026
Strength: 7.4/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ABCL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ABCL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $11.43, which is considered slightly high relative to its 30-day fair value range of $6.82 to $12.10.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $10.44, while resistance sits at $12.58.
Market Sentiment: ABCL scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.12 (+49.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABCL is in a strong uptrend. Immediate support is located at $10.44, while resistance sits at $12.58.
Market Sentiment: ABCL scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.12 (+49.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$6.82 -
$12.10
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (24/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 49.8% below Wall St target ($17.12)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.82 -
$12.10
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$10.44
Resistance Level
$12.58
Current Trend
Strong Uptrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.99
Wall Street Target
$17.13
(+49.8%)
Revenue Growth (YoY)
-76.3%
Earnings Growth (YoY)
45.9%
Profit Margin
-248.8%
Share & Embed Analysis
Last updated: September 05, 2026 10:22 PM ET
Data refreshes hourly during market hours. Next update: 11:22 PM
Data refreshes hourly during market hours. Next update: 11:22 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 40 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 38 SELL |
